Cholera Vaccine, Live Dosage

Medically reviewed by Drugs.com. Last updated on Dec 11, 2023.

Usual Adult Dose for Vaccination

18 to 64 years: 100 mL orally once, at least 10 days before potential exposure to cholera

Comments:

Patients should avoid eating or drinking 60 minutes before and after taking this drug.

Use: For active immunization against disease caused by Vibrio cholerae serogroup O1 in patients traveling to cholera-affected areas

Usual Adult Dose for Cholera Prophylaxis

18 to 64 years: 100 mL orally once, at least 10 days before potential exposure to cholera

Comments:

Patients should avoid eating or drinking 60 minutes before and after taking this drug.

Use: For active immunization against disease caused by Vibrio cholerae serogroup O1 in patients traveling to cholera-affected areas

Usual Pediatric Dose for Vaccination

2 to less than 6 years: 50 mL orally once, at least 10 days before potential exposure to cholera
6 to less than 18 years: 100 mL orally once, at least 10 days before potential exposure to cholera

Comments:

Patients should avoid eating or drinking 60 minutes before and after taking this drug.

Use: For active immunization against disease caused by V cholerae serogroup O1 in patients traveling to affected areas

Usual Pediatric Dose for Cholera Prophylaxis

Patients should avoid eating or drinking 60 minutes before and after taking this drug.

Use: For active immunization against disease caused by V cholerae serogroup O1 in patients traveling to affected areas

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

Patients with a history of severe allergic reaction (e.g., anaphylaxis) to the active component or to any of the ingredients of the vaccine, or to previous doses of any cholera vaccine

Safety and efficacy have not been established in patients younger than 2 years OR older than 65 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

For oral administration only
Avoid systemic antibiotic administration within 14 days prior to vaccination; antibiotics may prevent sufficient multiplication of the vaccine strain needed for a protective immune response.
Administer this vaccine at least 10 days before beginning antimalarial prophylaxis with chloroquine.
Avoid food or drink for 60 minutes before and after vaccination.
The final product must be consumed within 30 minutes of reconstitution if flavored with sucrose/non-flavored stevia OR within 4 hours if sweeteners have NOT been added.
Drink the full contents of the cup at once; some residue may remain and should be discarded with the cup.

Storage requirements:

Active and buffer components: Keep refrigerated at 2C to 8C (36F to 46F).
Packages may be stored 9C to 25C (48F to 77F) for no more than 5 days prior to reconstitution.
Protect from light and moisture.

Reconstitution/preparation techniques:

Prepare and administer in a healthcare setting equipped to dispose of medical waste.
Reconstitute after removing buffer and active component packets from refrigerator.
Pour 100 mL cold or room temperature bottled water (e.g., purified, spring, or sparkling/carbonated) into a disposable cup; do not use tap water, non-purified bottled water, or other beverages/liquids.
Add buffer component and stir until completely dissolved; effervescence will occur.
For children 2 to less than 6 years of age ONLY: Discard half (50 mL) of the buffer solution after mixing.
Add active component and stir for at least 30 seconds until it disperses into a cloudy suspension; add only approved sweeteners if desired.
If the packets are reconstituted in an improper order, discard vaccine.
Dispose of cup, packets, and stirrer according to standard procedures for medical waste.
Inactivate any spilled vaccine and clean any non-disposable equipment used in vaccine preparation with 70% isopropyl alcohol or 10% bleach solution.
Consult the manufacturer product information for illustrated preparation and reconstitution instructions.

General:

The safety and effectiveness of revaccination with this drug has not been established.
LIMITATIONS OF USE:
Effectiveness has not been established in persons living in cholera-affected areas OR in persons with pre-existing immunity from exposure to Vibrio cholerae or receipt of a cholera vaccine.
This vaccine has not been shown to protect against V cholerae serogroup O139 or other non-O1 serogroups.

Patient advice:

Read the US FDA-approved patient labeling (Vaccine Information Statement).
Patients should exercise caution regarding food and water consumed in cholera affected areas.
Report any adverse reactions to your health care provider; the most common adverse reactions occur within 7 days of vaccination.
This is a live, attenuated virus, and may be transmitted to close contacts.
For at least 14 days after vaccination, patients should wash their hands thoroughly after using the bathroom and before preparing or handling food.